BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum 2009;61:587-92. [PMID: 19404999 DOI: 10.1002/art.24462] [Cited by in Crossref: 59] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Jain V, Gordon C. Managing pregnancy in inflammatory rheumatological diseases. Arthritis Res Ther. 2011;13:206. [PMID: 21371350 DOI: 10.1186/ar3227] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
2 Tsao NW, Lynd LD, Sayre EC, Sadatsafavi M, Hanley G, De Vera MA. Use of biologics during pregnancy and risk of serious infections in the mother and baby: a Canadian population-based cohort study. BMJ Open 2019;9:e023714. [PMID: 30787081 DOI: 10.1136/bmjopen-2018-023714] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
3 Reino JG, Loza E, Andreu JL, Balsa A, Batlle E, Cañete JD, Collantes Estévez E, Fernández Carballido C, Fernández Sueiro JL, García de Vicuña R, González-álvaro I, González Fernández C, Juanola X, Linares LF, Marenco JL, Martín Mola E, Moreno Ramos M, Mulero Mendoza J, Muñoz Fernández S, Queiro R, Richi Alberti P, Sanz J, Tornero Molina J, Zarco Montejo P, Carmona L. Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas. Reumatología Clínica 2011;7:284-98. [DOI: 10.1016/j.reuma.2011.05.002] [Cited by in Crossref: 40] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
4 Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, Constantin A, Fautrel B, Gaudin P, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Huet I, Jullien D, Launay O, Lemann M, Maillefert JF, Marolleau JP, Martinez V, Masson C, Morel J, Mouthon L, Pol S, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Soubrier M, Sudre A, Tran TA, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011;78 Suppl 1:15-185. [PMID: 21703545 DOI: 10.1016/S1297-319X(11)70001-X] [Cited by in Crossref: 53] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
5 Ojeda-uribe M, Afif N, Dahan E, Sparsa L, Haby C, Sibilia J, Ternant D, Ardizzone M. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol 2013;32:695-700. [DOI: 10.1007/s10067-012-2156-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
6 Gall B, Yee A, Berry B, Bircham D, Hayashi A, Dansereau J, Hart J. Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura. J Obstet Gynaecol Can 2010;32:1167-71. [PMID: 21176329 DOI: 10.1016/S1701-2163(16)34741-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
7 Wakefield D, El-asrar AA, Mccluskey P. Treatment of Severe Inflammatory Eye Disease in Patients of Reproductive Age and during Pregnancy. Ocular Immunology and Inflammation 2012;20:277-87. [DOI: 10.3109/09273948.2012.684736] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
8 Molinelli E, Sapigni C, Campanati A, Brisigotti V, Offidani A. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa. Expert Opin Drug Metab Toxicol 2020;16:1019-37. [PMID: 32896186 DOI: 10.1080/17425255.2020.1810233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Narula N, Al-dabbagh R, Dhillon A, Sands BE, Marshall JK. Anti-TNFα Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflammatory Bowel Diseases 2014;20:1862-9. [DOI: 10.1097/mib.0000000000000092] [Cited by in Crossref: 51] [Cited by in F6Publishing: 12] [Article Influence: 7.3] [Reference Citation Analysis]
10 Fischer-Betz RE, Schneider M. [Biologics during pregnancy and breast--feeding]. Z Rheumatol 2010;69:780-7. [PMID: 21063826 DOI: 10.1007/s00393-010-0640-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
11 Papagoras C, Drosos AA. Abatacept: a biologic immune modulator for rheumatoid arthritis. Expert Opinion on Biological Therapy 2011;11:1113-29. [DOI: 10.1517/14712598.2011.592825] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
12 Clowse ME, Feldman SR, Isaacs JD, Kimball AB, Strand V, Warren RB, Xibillé D, Chen Y, Frazier D, Geier J, Proulx J, Marren A. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. Drug Saf 2016;39:755-62. [PMID: 27282428 DOI: 10.1007/s40264-016-0431-z] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 16.8] [Reference Citation Analysis]
13 Cordero-coma M, Salazar-méndez R, Yilmaz T. Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues. Expert Opinion on Drug Safety 2015;14:1071-86. [DOI: 10.1517/14740338.2015.1044969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Ateka-Barrutia O, Khamashta MA. The challenge of pregnancy for patients with SLE. Lupus 2013;22:1295-308. [PMID: 24098002 DOI: 10.1177/0961203313504637] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
15 Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, Spitz B, Hoffman I, Van Steen K, Vermeire S. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011;17:1846-1854. [PMID: 21830263 DOI: 10.1002/ibd.21583] [Cited by in Crossref: 127] [Cited by in F6Publishing: 117] [Article Influence: 12.7] [Reference Citation Analysis]
16 Fumarola A, Di Fiore A, Dainelli M, Grani G, Carbotta G, Calvanese A. Therapy of Hyperthyroidism in Pregnancy and Breastfeeding. Obstetrical & Gynecological Survey 2011;66:378-85. [DOI: 10.1097/ogx.0b013e31822c6388] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
17 Barnea ER, Rambaldi M, Paidas MJ, Mecacci F. Reproduction and autoimmune disease: important translational implications from embryo–maternal interaction. Immunotherapy 2013;5:769-80. [DOI: 10.2217/imt.13.59] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
18 Gómez Reino J, Loza E, Andreu JL, Balsa A, Batlle E, Cañete JD, Collantes Estévez E, Fernández Carballido C, Fernández Sueiro JL, García de Vicuña R, González-álvaro I, González Fernández C, Juanola X, Linares LF, Marenco JL, Martín Mola E, Moreno Ramos M, Mulero Mendoza J, Muñoz Fernández S, Queiro R, Richi Alberti P, Sanz J, Tornero Molina J, Zarco Montejo P, Carmona L. Consensus Statement of the Spanish Society of Rheumatology on Risk Management of Biologic Therapy in Rheumatic Patients. Reumatología Clínica (English Edition) 2011;7:284-98. [DOI: 10.1016/j.reumae.2011.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Porres-Aguilar M, Figueroa-Casas JB, Porres-Muñoz M, Elliott CG. A 38-year-old pregnant woman with hemoptysis and acute renal failure. Microscopic polyangiitis. Respiration 2011;82:60-4. [PMID: 21555869 DOI: 10.1159/000327174] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
20 Ruiz-Irastorza G, Khamashta MA. Lupus and pregnancy: integrating clues from the bench and bedside. Eur J Clin Invest. 2011;41:672-678. [PMID: 21158850 DOI: 10.1111/j.1365-2362.2010.02443.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
21 Bugelski PJ, Martin PL. Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. Br J Pharmacol 2012;166:823-46. [PMID: 22168282 DOI: 10.1111/j.1476-5381.2011.01811.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
22 Pefanis A, Williams DS, Skrzypek H, Fung A, Paizis K. A case of ANCA-associated vasculitis presenting de novo in pregnancy, successfully treated with rituximab. Obstet Med 2020;13:41-4. [PMID: 32284732 DOI: 10.1177/1753495X18780853] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ngian GS, Briggs AM, Ackerman IN, Van Doornum S. Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation. Int J Rheum Dis 2016;19:834-43. [PMID: 27125255 DOI: 10.1111/1756-185X.12860] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
24 Kavanaugh A, Cush JJ, Ahmed MS, Bermas BL, Chakravarty E, Chambers C, Clowse M, Curtis JR, Dao K, Hankins GDV, Koren G, Kim SC, Lapteva L, Mahadevan U, Moore T, Nolan M, Ren Z, Sammaritano LR, Seymour S, Weisman MH. Proceedings From the American College of Rheumatology Reproductive Health Summit: The Management of Fertility, Pregnancy, and Lactation in Women With Autoimmune and Systemic Inflammatory Diseases: Pregnancy in Autoimmune and Systemic Inflammatory Diseases. Arthritis Care & Research 2015;67:313-25. [DOI: 10.1002/acr.22516] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
25 Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf 2014. [DOI: 10.1517/14740338.2015.973399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Nielsen OH, Loftus EV, Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med. 2013;11:174. [PMID: 23902720 DOI: 10.1186/1741-7015-11-174] [Cited by in Crossref: 80] [Cited by in F6Publishing: 71] [Article Influence: 10.0] [Reference Citation Analysis]
27 Saavedra Salinas MÁ, Barrera Cruz A, Cabral Castañeda AR, Jara Quezada LJ, Arce-salinas CA, Álvarez Nemegyei J, Fraga Mouret A, Orozco Alcalá J, Salazar Páramo M, Cruz Reyes CV, Andrade Ortega L, Vera Lastra OL, Mendoza Pinto C, Sánchez González A, Cruz Cruz PDR, Morales Hernández S, Portela Hernández M, Pérez Cristóbal M, Medina García G, Hernández Romero N, Velarde Ochoa MDC, Navarro Zarza JE, Portillo Díaz V, Vargas Guerrero A, Goycochea Robles MV, García Figueroa JL, Barreira Mercado E, Amigo Castañeda MC. Guías de práctica clínica para la atención del embarazo en mujeres con enfermedades reumáticas autoinmunes del Colegio Mexicano de Reumatología. Parte II. Reumatología Clínica 2015;11:305-15. [DOI: 10.1016/j.reuma.2014.12.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
28 Soh MC, Nelson-piercy C. Update of the management of rheumatoid arthritis in pregnancy. Expert Review of Obstetrics & Gynecology 2014;7:77-96. [DOI: 10.1586/eog.11.77] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
29 Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf. 2014;13:1699-1708. [PMID: 25406728 DOI: 10.1517/14740338.2014.973399] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
30 Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford). 2014;53:1377-1385. [PMID: 24352337 DOI: 10.1093/rheumatology/ket409] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 9.1] [Reference Citation Analysis]
31 Ellinger I, Fuchs R. HFcRn-mediated transplacental immunoglobulin G transport: protection of and threat to the human fetus and newborn. Wien Med Wochenschr 2012;162:207-13. [PMID: 22717875 DOI: 10.1007/s10354-012-0085-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
32 Rump JA, Schönborn H. [Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment]. Z Rheumatol. 2010;69:903-909. [PMID: 20532789 DOI: 10.1007/s00393-010-0652-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
33 Rodríguez Lozano C. Seguridad de las terapias biológicas: nuevos datos de BIOBADASER. Reumatología Clínica 2011;6:1-6. [DOI: 10.1016/j.reuma.2010.11.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Martineau M, Haskard DO, Nelson-Piercy C. Behçet's syndrome in pregnancy. Obstet Med 2010;3:2-7. [PMID: 27582833 DOI: 10.1258/om.2009.090033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426-1438. [PMID: 23752881 DOI: 10.1038/ajg.2013.171] [Cited by in Crossref: 84] [Cited by in F6Publishing: 78] [Article Influence: 10.5] [Reference Citation Analysis]
36 Harris C, Marin J, Beaulieu MC. Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report. BMC Nephrol 2018;19:152. [PMID: 29954345 DOI: 10.1186/s12882-018-0949-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
37 Soh MC, Mackillop L. Biologics in pregnancy - for the obstetrician. Obstet Gynecol 2016;18:25-32. [DOI: 10.1111/tog.12250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
38 Sangle SR, Lutalo PM, Davies RJ, Khamashta MA, D’Cruz DP. B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases. J Autoimmun. 2013;43:55-59. [PMID: 23608146 DOI: 10.1016/j.jaut.2013.03.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
39 Perng P, Zampella JG, Okoye GA. Management of hidradenitis suppurativa in pregnancy. Journal of the American Academy of Dermatology 2017;76:979-89. [DOI: 10.1016/j.jaad.2016.10.032] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
40 Andreoli L, Bazzani C, Taraborelli M, Reggia R, Lojacono A, Brucato A, Meroni PL, Tincani A. Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges. Autoimmun Rev 2010;10:51-4. [PMID: 20696283 DOI: 10.1016/j.autrev.2010.08.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]